In plain words
as of 20 Nov 2026This fund does not have enough history yet for a reading. Most numbers need at least a year, risk numbers need three.
Key facts
- Fund house
- Nippon India Mutual Fund
- Category
- Sectoral / Thematic (SEBI)
- Plan & option
- Direct · Bonus
- Benchmark i
- NIFTY Pharma TRI (tracked via Nippon India Nifty Pharma ETF - Direct Plan)
- First NAV
- 3 Jan 2013 · — of history · 3,415 NAVs
- AMFI code
- 118758
- ISIN
- INF204K01I27
- Expense ratio i
- 0.98%
- Fund size
- ₹9,087 Cr
How ₹100 grew
Returns
Up to 1 year: total change. Longer: yearly (CAGR) i| 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 7Y | 10Y | Since launch | |
|---|---|---|---|---|---|---|---|---|---|---|
| This fund | — | — | — | — | — | — | — | — | — | — |
| NIFTY Pharma TRI* | +10.85% | +7.49% | +14.67% | +25.66% | +25.86% | +22.31% | +16.87% | — | — | — |
| Sectoral / Thematic middle fund i | +7.06% | +0.76% | +8.56% | +4.78% | +4.51% | +14.52% | +13.44% | +17.70% | +15.67% | — |
Category middle = median Direct Growth fund in Sectoral / Thematic (145 funds with 3 years). * Benchmark approximated by Nippon India Nifty Pharma ETF - Direct Plan with its expense ratio added back. Blank means not enough history, never zero.
Risk and risk-adjusted return
Last 36 months · risk-free rate 6.5%Against its benchmark
NIFTY Pharma TRI · 36 monthly returnsThe worst it has been
Every 1-year period i
One 5-year number depends on its start date. These show what happened across every start date in the fund's life.
What it holds
filed for 31 Oct 2026Asset mix
Company size
How concentrated
Largest sector: Pharmaceuticals & Biotechnology at 75.0%.
Largest holdings
| Holding | Sector | Weight |
|---|---|---|
| Sun Pharmaceutical Industries Limited | Pharmaceuticals & Biotechnology | 11.55% |
| Divi's Laboratories Limited | Pharmaceuticals & Biotechnology | 6.73% |
| Cipla Limited | Pharmaceuticals & Biotechnology | 6.21% |
| Lupin Limited | Pharmaceuticals & Biotechnology | 6.16% |
| Dr. Reddy's Laboratories Limited | Pharmaceuticals & Biotechnology | 6.13% |
| Apollo Hospitals Enterprise Limited | Healthcare Services | 5.10% |
| Mankind Pharma Limited | Pharmaceuticals & Biotechnology | 4.40% |
| Sai Life Sciences Limited | Pharmaceuticals & Biotechnology | 4.04% |
| Ajanta Pharma Limited | Pharmaceuticals & Biotechnology | 3.53% |
| Max Healthcare Institute Limited | Healthcare Services | 3.31% |
| IPCA Laboratories Limited | Pharmaceuticals & Biotechnology | 2.90% |
| GlaxoSmithKline Pharmaceuticals Limited | Pharmaceuticals & Biotechnology | 2.83% |
| Gland Pharma Limited | Pharmaceuticals & Biotechnology | 2.73% |
| Vijaya Diagnostic Centre Limited | Healthcare Services | 2.66% |
| Piramal Pharma Limited | Pharmaceuticals & Biotechnology | 2.61% |
| MedPlus Health Services Limited | Retailing | 2.26% |
| Fortis Healthcare Limited | Healthcare Services | 2.25% |
| Abbott India Limited | Pharmaceuticals & Biotechnology | 2.22% |
| Dr. Lal Path Labs Limited | Healthcare Services | 2.10% |
| Thyrocare Technologies Limited | Healthcare Services | 1.93% |
| Alkem Laboratories Limited | Pharmaceuticals & Biotechnology | 1.82% |
| Narayana Hrudayalaya Limited | Healthcare Services | 1.56% |
| Syngene International Limited | Healthcare Services | 1.55% |
| Aurobindo Pharma Limited | Pharmaceuticals & Biotechnology | 1.42% |
| Suraksha Diagnostic Limited | Healthcare Services | 1.36% |
| Emcure Pharmaceuticals Limited | Pharmaceuticals & Biotechnology | 1.32% |
| Anthem Biosciences Limited | Pharmaceuticals & Biotechnology | 1.30% |
| Pfizer Limited | Pharmaceuticals & Biotechnology | 1.29% |
| Akums Drugs and Pharmaceuticals Limited | Pharmaceuticals & Biotechnology | 1.09% |
| Sanofi India Limited | Pharmaceuticals & Biotechnology | 1.06% |
| Biocon Limited | Pharmaceuticals & Biotechnology | 0.97% |
| Natco Pharma Limited | Pharmaceuticals & Biotechnology | 0.90% |
| Sanofi Consumer Healthcare India Limited | Pharmaceuticals & Biotechnology | 0.81% |
| Molbio Diagnostics Limited | Healthcare Equipment & Supplies | 0.53% |
| AstraZeneca Pharma India Limited | Pharmaceuticals & Biotechnology | 0.46% |
| Indoco Remedies Limited | Pharmaceuticals & Biotechnology | 0.38% |
| Concord Biotech Limited | Pharmaceuticals & Biotechnology | 0.15% |
Sectors
What the manager did last month
30 Sep 2026 → 31 Oct 2026A holding's value moves with its price; only a change in the number of shares is a decision. These lists use share counts. A split or bonus also changes share counts, so check sudden round multiples.
New 1
Added to 5
Trimmed 3
Against similar funds
Top Sectoral / Thematic Direct Growth funds by return. A sort by one past number, not a recommendation.
| Fund | Return | Volatility | Sharpe | Alpha | Beta | Deepest fall | Stars |
|---|---|---|---|---|---|---|---|
| HDFC Defence Fund HDFC | +31.36% | 30.9% | 0.80 | — | — | −34.54% | ★★★★★ |
| Nippon India Taiwan Equity Fund Nippon India | +31.07% | 42.4% | 0.58 | +30.87% | −0.14 | −47.10% | ★★★★★ |
| HDFC Pharma and Healthcare Fund HDFC | +30.70% | 15.8% | 1.53 | +7.54% | 0.97 | −14.91% | ★★★★★ |
| SBI HEALTHCARE OPPORTUNITIES FUND SBI | +24.78% | 14.1% | 1.30 | +5.20% | 0.86 | −30.53% | ★★★★★ |
| HDFC Transportation and Logistics Fund HDFC | +24.43% | 19.1% | 0.94 | +11.22% | 1.02 | −23.50% | ★★★★★ |
| Mirae Asset Healthcare Fund Mirae Asset | +24.02% | 15.5% | 1.13 | +3.31% | 0.96 | −19.98% | ★★★★★ |
| UTI - Healthcare Fund UTI | +23.24% | 15.4% | 1.09 | +3.12% | 0.91 | −27.10% | ★★★★★ |
| Aditya Birla Sun Life Transportation and Logistics Fund ABSL | +23.16% | 19.9% | 0.84 | +9.65% | 1.09 | −28.25% | Not rated |
| ICICI PRUDENTIAL TRANSPORTATION AND LOGISTICS FUND ICICI Pru | +22.67% | 18.9% | 0.86 | +9.34% | 1.06 | −23.58% | ★★★★★ |
| LIC MF Healthcare Fund LIC | +21.83% | 15.5% | 0.99 | +2.28% | 0.90 | −15.10% | ★★★★★ |
Compare side by side with another Sectoral / Thematic fund
All plans and options
| Scheme | NAV | AMFI code |
|---|---|---|
| Direct · Growth | ₹666.3420 | 118759 |
| Direct · Bonus | ₹666.3420 | 118758 |
| Direct · IDCW | ₹182.3637 | 118756 |
| Regular · Growth | ₹591.2429 | 102431 |
| Regular · Bonus | ₹591.2429 | 102432 |
| Regular · IDCW | ₹127.6754 | 102433 |
About Sectoral / Thematic funds
- The rule
- At least 80% in one sector (banking, pharma, IT ...) or theme (consumption, manufacturing ...).
- Who it can suit
- Investors adding a deliberate bet on top of a diversified core.
- Typical holding period
- 7 years or more
Questions people ask
What is the NAV of Nippon India Pharma Fund?
₹666.3420 as of 20 Nov 2026, from AMFI's daily NAV file. NAVs are published once every business day after markets close.
Direct or Regular: what is the difference?
Same portfolio. Regular pays a distributor commission inside its fee, so it returns a little less every year.
Growth or IDCW?
Growth reinvests everything. IDCW pays some out, so its NAV drops after each payout and its NAV-based return understates what investors received.
How are these numbers calculated?
Every figure is computed by Growth from the fund's published NAV history. See How we calculate.